OPERA-02
22 evidence topics · 8 sources
Objective
Location and study date
Registry dates and planned enrollment
| Item | Value |
|---|---|
| Study start (actual) | “2025-11-03” |
| Primary completion (estimated) | “2028-12” |
| Study completion (estimated) | “2032-01” |
Study design
Randomized, double-blind, active-controlled design
Stratification factors and randomization ratio
Eligibility criteria
Key inclusion criteria
Key exclusion criteria
Prior endocrine therapy exclusions in the registry record
Treatment
Investigational and control regimens
Study outcomes
Rationale for using investigator-assessed progression-free survival as the primary endpoint
Primary, key secondary, and other secondary endpoints
| Endpoint role | Endpoint |
|---|---|
| Primary endpoint | “PFS, as assessed by local investigator” |
| Key secondary endpoint | “OS” |
| Other secondary endpoint | “PFS (per BIRC)” |
| Other secondary endpoint | “ORR, CBR, and DOR (per local investigator and BIRC)” |
| Other secondary endpoint | “PFS2” |
| Other secondary endpoint | “Safety and tolerability” |
| Other secondary endpoint | “PK” |
| Other secondary endpoint | “Patient-reported outcomes” |
Registry definition of the primary outcome
Regulatory rationale for progression-free survival
Statistical analysis description
Number of participants (Planned and analyzed)
Planned participants per arm
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
No results from OPERA-02 have been reported; primary completion is estimated for December 2028, and top-line data are anticipated in 2028. The trial enrolls participants with no prior systemic therapy for advanced breast cancer and tests palazestrant in combination with ribociclib, so its population and regimen are outside this indication of previously treated disease and palazestrant monotherapy. The primary endpoint is investigator-assessed PFS, with PFS by blinded independent central review as a secondary endpoint. Participants previously treated with fulvestrant, elacestrant, or an investigational endocrine therapy in any setting are excluded.